NFE2L2 and Parkinson disease: Therefore, small‐molecule inhibitors of ferroptosis, including iron chelators, ROS scavengers, and activators of the nuclear factor (erythroid‐derived 2)‐like 2 (NRF2) endogenous antioxidant pathway, hold significant therapeutic potential for PD treatment [6].